Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)
| Market Cap | 122.44M+32.3% |
| Revenue (ttm) | 0-100.0% |
| Net Income | -174.90M-7.4% |
| EPS | -2.46-8.4% |
| Shares Out | 71.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,294,167 |
| Open | 1.72 |
| Previous Close | 1.71 |
| Day's Range | 1.71 - 1.82 |
| 52-Week Range | 1.21 - 6.95 |
| Beta | 1.93 |
| Analysts | Buy |
| Price Target | 7.67(+345.93%) |
| Earnings Date | Nov 10, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About ZNTL
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating ZNTL in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Nov 10, 2026Earnings report
Ask Barron about ZNTL
$ZNTL stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ZNTL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ZNTL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ZNTL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ZNTL Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Azenosertib external development costs | $23.69M | 86.06% |
| Other | $2.10M | 7.65% |
| Changes in working capital | $1.73M | 6.29% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ZNTL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ZNTL from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ZNTL
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $7.91M |
| IWMiShares Russell 2000 ETF | $2.26M |
| VXFVanguard Extended Market ETF | $1.60M |
| VFMOVanguard U.S. Momentum Factor ETF | $1.07M |
| FESMFidelity Enhanced Small Cap ETF | $1.07M |
| IWNiShares Russell 2000 Value ETF | $834.50K |
Estimated from each fund’s disclosed top holdings × AUM
ZNTL Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ZNTL’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
Biotech: 99 sector peers carry a ranked score; this one has no qualifying buying in the window · sector average 59.3
What’s Behind the Score
News check: Positive clinical data for lead candidate azenosertib showing meaningful survival benefits in ovarian cancer; administrative news is neutral.
Recent Insider Activity
Insider Score Trend Over Time
-61.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.